Should I Buy SERA? SERA 2026 Analysis

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.990

1 Day change

-1.97%

52 Week Range

4.090

Analysis Updated At

2026/03/20

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Sera Prognostics Inc (SERA) is not a strong buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with declining revenues, significant net losses, and no clear positive catalysts to drive growth. Additionally, insider selling and bearish technical indicators suggest caution.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 25.913, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 1.747, with resistance at 2.038. Overall, the technical indicators do not suggest a strong upward trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The company holds $95.8 million in cash reserves, which provides financial stability. Additionally, new leadership and plans to expand partner programs to cover 58%-60% of U.S. births could potentially drive future growth.

Neutral/Negative Catalysts

There are also no recent congress trading data or strong trading trends to support a buy decision.

Financial Performance

In Q4 2025, revenue dropped to $10,000 (-58.33% YoY), net income dropped to -$7.88 million (-8.14% YoY), and EPS fell to -$0.16 (-36% YoY). Despite these challenges, the company has $95.8 million in cash reserves, which provides some financial stability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for SERA.

3 Analyst Rating

Wall Street analysts forecast SERA stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.030

Low

Averages

High

Current: 2.030

Low

Averages

High

Jefferies

initiated

AI Analysis

2025-12-14

Reason

Jefferies

Price Target

AI Analysis

2025-12-14

initiated

Reason

Jefferies initiated coverage of Sera Prognostics with a Buy rating and $5 price target. Sera is a women's health diagnostics company developing predictive biomarker testing for pregnancy complications, the analyst tells investors in a research note. The firm says the company's flagship product PreTRM offers a simple blood test for predicting individualized risk for spontaneous preterm birth in asymptomatic pregnancies. Jefferies cites PreTRM's first to market clinical validation, "attractive" $1.6B addressable market in the U.S. and its early traction with Elevance partner and Medicaid pilot programs for the Buy rating.

SERA Should I Buy

SERA Should I Buy

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch